Metropolitan Life Insurance Company (MetLife)’s Keros Therapeutics KROS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,353	Closed	-$89.6K	–	1139
2024 Q1	$89.6K	Sell	1,353 -71	-5%	-$4.21K	﹤0.01%	1103
2023 Q4	$56.6K	Hold	1,424	–	–	﹤0.01%	1381
2023 Q3	$45.4K	Buy	1,424 +192	+16%	+$7.17K	﹤0.01%	1457
2023 Q2	$49.5K	Buy	1,232 +190	+18%	+$8.33K	﹤0.01%	1420
2023 Q1	$44.5K	Sell	1,042 -149	-13%	-$7.53K	﹤0.01%	1452
2022 Q4	$57.2K	Buy	1,191 +108	+10%	+$5.04K	﹤0.01%	1389
2022 Q3	$40.7K	Hold	1,083	–	–	﹤0.01%	1599
2022 Q2	$29.9K	Hold	1,083	–	–	﹤0.01%	1821
2022 Q1	$58.9K	Sell	1,083 -2,999	-73%	-$154K	﹤0.01%	1503
2021 Q4	$239K	Hold	4,082	–	–	﹤0.01%	1903
2021 Q3	$161K	Hold	4,082	–	–	﹤0.01%	2246
2021 Q2	$173K	Buy	4,082 +270	+7%	+$14.6K	﹤0.01%	2253
2021 Q1	$235K	Hold	3,812	–	–	﹤0.01%	1910
2020 Q4	$269K	Buy	3,812 +1,181	+45%	+$74.4K	﹤0.01%	1739
2020 Q3	$101K	Hold	2,631	–	–	﹤0.01%	2213
2020 Q2	$98.7K	Buy	+2,631	New	+$81.1K	﹤0.01%	2262

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s KROS Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Keros Therapeutics (KROS) in Q2 2024, closing a stake of 1,353 shares — an estimated $89.6K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in KROS in Q2 2020 and held it in 16 quarters. The position peaked at $269K in Q4 2020. 152 funds tracked by Wall St. Rank hold KROS as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Keros Therapeutics position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,353 Keros Therapeutics shares in Q2 2024, an estimated $89.6K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Keros Therapeutics in Q2 2020 and held it in 16 quarters.
Metropolitan Life Insurance Company (MetLife)'s Keros Therapeutics position peaked at $269K in Q4 2020.
152 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.